ライフサイエンスコーパス: immunity (against|to)

1 However, pre-existing immunity to 10403S did not confer protection in the brai

2 We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (

3 tis as a vaccine strategy to induce adaptive immunity against a foreign, crosslinked protein, chicken

4 ings suggest that vaccine-induced protective immunity against a murine model of experimental Q fever

5 enhancing both innate and adaptive antiviral immunity against a variety of viral pathogens, such as,

6 y to include a role in regulating antifungal immunity against A. fumigatus.

7 ion as "biological preparations that improve immunity to a particular disease," represents one of the

8 es as a key node in the induction of humoral immunity against AAV serotypes.

9 T-6 Delta92-95) are safe and confer superior immunity against aerosol Mtb infection in the context of

10 ully designed to guarantee fair sampling and immunity to all known side channels(24,25).

11 fore, ideal vaccine candidates should elicit immunity to all lineages.

12 lates T(H) cell phenotypes and can dampen T2 immunity to allergens, but its functions in controlling

13 gnaling is essential for driving T(H) 2-type immunity to allergens.

14 of the mechanisms involved in the protective immunity to alpha-Gal and discuss the possibilities and

15 sense microbial patterns and activate innate immunity against attempted microbial invasions.

16 cell death (ICD), can propagate antitumoral immunity to augment therapeutic efficacy.

17 oxygen species during both PTI and ETI, and immunity against avirulent bacteria and a virulent necro

18 ectives included the evaluation of augmented immunity against bacterial and fungal infection, as well

19 or two WRKYs as positive regulators of plant immunity against bacterial and potentially non-bacterial

20 ytosphingosine and thereby promotes stomatal immunity against bacterial pathogens.

21 ntify a novel role for FSTL-1 in innate lung immunity to bacterial infection, suggesting that FSTL-1

22 d represent an important determinant of host immunity to bacterial pathogens.

23 The role of FSTL-1 in immunity to bacterial pneumonia is unknown.

24 non-pathogenic E. coli, this pathway confers immunity against bacteriophage lambda through an abortiv

25 tor of interferon genes (STING) links innate immunity to biological processes ranging from antitumor

26 As IFN-gamma is essential for protective immunity against Bp we investigated how IFN-gamma is ind

27 results establish, for the first time, that immunity to BREX system defense is provided by an epigen

28 rther confirming that CD4(+) T cell-mediated immunity against Brucella is inhibited by B cells.

29 minal region, was shown to elicit protective immunity against C. difficile and is under consideration

30 PI-WVC stimulates protective immunity to C. burnetii in mice through stimulation of m

31 cells that activated CD8(+) T cell-mediated immunity against cancer.

32 ymph node, indicating the potential for DENV immunity to cause ADE in vivo.

33 of both natural(1) and vaccine-induced(2-7) immunity against challenge with severe acute respiratory

34 enitor-like CD8(+) T cells mediate long-term immunity to chronic infection and cancer and respond pot

35 Thus, long-term CD8(+) T cell immunity to chronic viral infection requires unique tran

36 otective: in children before they have built immunity to circulating strains and in response to novel

37 e GCP-rCpa1 vaccine stimulates a robust Th17 immunity against Coccidioides infection through activati

38 Here we show that T cell immunity against commensal papillomaviruses suppresses s

39 pidly quantify PCr concentration with robust immunity to commonly seen MRI interferences.

40 ral role of Cas9 in CRISPR-mediated adaptive immunity to contemporary efforts aimed at developing and

41 at their foundation, IFNs can widely reshape immunity to control infectious diseases and malignancies

42 review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well

43 tions to enhance NAD levels may boost innate immunity to coronaviruses.

44 The lack of prior immunity to COVID-19 has resulted in large numbers of in

45 a leading treatment for conferring temporary immunity to COVID-19-susceptible individuals or for use

46 Protective immunity against Coxiella burnetii infection is conferre

47 Protective immunity to cutaneous leishmaniasis is mediated by IFN-g

48 Our data suggest immunity to DENV only modestly shapes breadth and magnit

49 stemic, so as to better understand effective immunity to develop improved approaches to treat inflamm

50 ediatric model of disease, transmission, and immunity to develop preventive and therapeutic strategie

51 differences in parasite transmissibility and immunity to different genotypes.

52 e chaperones could work in concert with host immunity to disable Mtb.

53 l assays show that RNase J2 is essential for immunity against diverse mobile genetic elements origina

54 equirement for a key host mediator of innate immunity to DNA viruses in the life cycle of a small pat

55 for the development of sufficient population immunity to drive cessation of the coronavirus disease o

56 accine regimen is safe and provides specific immunity against Ebola glycoprotein, and is currently in

57 Antibodies are essential for immunity against Ehrlichia chaffeensis, and protective m

58 mechanisms by which CHIKV subverts antiviral immunity to establish and maintain a persistent infectio

59 , for instance, how RHV evades host adaptive immunity to establish persistent infection.

60 at potential in spintronics because of their immunity to external magnetic disturbance, the absence o

61 Our data demonstrate that IgG1(+) B-cell immunity against food allergens in epicutaneous sensitiz

62 okaryotes with a nucleic-acid-based adaptive immunity against foreign DNA.

63 Type III CRISPR-Cas systems provide immunity to foreign DNA by targeting its transcripts.

64 ation of ZIKV vaccines that could also boost immunity against future DENV epidemics.

65 chaeal CRISPR-Cas systems provide RNA-guided immunity against genetic invaders such as bacteriophages

66 tance of functional antigen-specific humoral immunity to guide patient care and vaccine development.

67 enza and determined clearance and protective immunity to H3N2 virus.

68 CMV infections (cCMV) in women with existing immunity to HCMV, infections that have been designated a

69 Their role in plant immunity against hemibiotrophic fungal infection remains

70 llular m(6)A machinery regulates host innate immunity against hepatitis B and C viral infections by i

71 tures of affected subjects, such as impaired immunity to herpesviruses and tumor surveillance.

72 lenged with H3N2, generated cross-protective immunity to heterosubtypic H3N2 influenza strain whereas

73 cal and effective route to induce protective immunity against HIV-1.

74 ation of the infant immune system influences immunity to HIV infection or how these responses differ

75 e-based approaches, and understanding infant immunity to HIV is critical to guide the rational design

76 ot surprising that elicitation of protective immunity to HIV-1 has not yet been possible.

77 hogen, the human population has pre-existing immunity to HPIV-3, which may restrict the replication o

78 rols central nervous system neuron-intrinsic immunity to HSV-1 by a distinctive mechanism.

79 We conclude that innate immunity to HSV-1 is normally repressed in unstressed ce

80 bited impaired IFN responses and compromised immunity to HSV-1.

81 es to program DCs to direct effective T cell immunity against IAV.

82 factors, limited protection from preexisting immunity against IDVs in cattle herds and cocirculation

83 ght the difficulties in eliciting protective immunity against immunodeficiency virus infection.IMPORT

84 dicate that bacteriophages can alter mucosal immunity to impact mammalian health.

85 s of immunotherapeutics that activate innate immunity to increase tumour immunogenicity.

86 infection causes changes in the transfer of immunity to infants remains unclear.

87 inted at understanding the complex issues of immunity to infection and disease caused by influenza vi

88 derstanding of their functional role in host immunity to infection is just emerging.

89 recently emerged as central orchestrators of immunity to infection, inflammation, and neoplastic dise

90 of several T lymphocyte subsets that provide immunity to infection, mediate inflammation and prevent

91 evaluating their role in host differences of immunity to infection.

92 intrinsic anti-microbial capacity of innate immunity to infection.

93 manner without suppressing local or systemic immunity against infectious agents or cancer.

94 wnstream CD8(+) T cell memory and protective immunity against infectious challenge.

95 responses and has the potential to regulate immunity against infectious disease.

96 fers from prophylactic vaccines that provoke immunity to infectious agents, as in allergy the patient

97 neutralizing antibodies that confer lasting immunity to infectious diseases including smallpox, meas

98 nation is widely used to generate protective immunity against influenza virus.

99 ence supports a critical role of CD8+ T-cell immunity against influenza.

100 Higher levels of preexisting immunity to influenza A/H3N2 and B were strongly associa

101 r 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-th

102 Immunity to influenza viruses can be long-lived, but rei

103 cells are a central component of protective immunity to influenza, delivering direct effector functi

104 phasize the potential for studies of passive immunity to inform the selection of immunogens as candid

105 cells as neurons using components of innate immunity to interact with the microbial environment and

106 r cross-presentation and CD8 T cell-mediated immunity against intracellular pathogens and tumors.

107 Neonates often develop poor immunity against intracellular pathogens.

108 has an essential role in innate and adaptive immunity to intracellular bacteria.

109 ve had great difficulty achieving protective immunity against it in rhesus monkey models.

110 e ELISA was poor (77.1%) among children with immunity to just one dengue virus serotype.

111 s provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural

112 d the role of Semaphorin 3E (Sema3E) in host immunity to Leishmania major infection in mice.

113 ample, the placenta, enhancing fetal humoral immunity to levels similar to their mothers'.

114 studies suggest the existence of protective immunity against LF in humans.

115 e to attenuated vaccines may enhance trained immunity to limit excessive immune reaction to COVID-19

116 entify multiple compounds that modulate host immunity to limit mycobacterial disease, including the i

117 Host organisms utilize nutritional immunity to limit the availability of nutrients essentia

118 ed and maintained and how such cells mediate immunity to liver-stage malaria.

119 appear to play integral roles in protective immunity to liver-stage malaria.

120 Ns) are key sites for orchestrating adaptive immunity to luminal perturbations(5-7).

121 resenting cells (APCs) to enhance anticancer immunity against lung metastases.

122 pulations, which have not evolved protective immunity to M. gallisepticum We show using 3 different m

123 t on the importance of effector functions in immunity against MACV.IMPORTANCE MACV infections are a s

124 ifies cellular events that underpin mosquito immunity to malaria infection.

125 1, poses a barrier to identifying targets of immunity to malaria.

126 otes they mediate protective roles in innate immunity against malignant, viral, and bacterial disease

127 re are no known resistance genes that confer immunity to MCMV.

128 Immunity to measles, mumps, rubella, and varicella-zoste

129 nce, there is concurrent need for protective immunity to meet the antigenic challenges encountered af

130 ic T-cell suppression are also important for immunity against microbial pathogens as well as oncogeni

131 ic T cell suppression are also important for immunity against microbial pathogens as well as oncogeni

132 biological processes ranging from antitumor immunity to microbiome homeostasis.

133 ge GTPase which is crucial to the protective immunity against microorganisms.

134 lance of endogenous and exogenous sources of immunity to mitigate parasite attack.

135 categorized by ACIP criteria for presumptive immunity to MMRV.

136 The CRISPR system provides adaptive immunity against mobile genetic elements in prokaryotes.

137 em in bacteria and archaea provides adaptive immunity against mobile genetic elements.

138 s pathway in prokaryotes for developing host immunity to mobile genetic elements.

139 In animal models, immunity to mosquito salivary proteins protects animals

140 ring motion shows drawn-on-skin electronics' immunity to motion artifacts.

141 spectively, which confers protective trained immunity against Mtb.

142 the IFN-I/iron axis in HSCs impairs trained immunity to Mtb infection.

143 nd impairs development of protective trained immunity to Mtb.

144 asize the importance of providing protective immunity to neonates during this window of vulnerability

145 Innate immunity to nucleic acids forms the backbone for anti-vi

146 +) CD4(+) T cells associated with protective immunity against ocular herpes infection and disease.IMP

147 e cornea that was associated with protective immunity against ocular herpes.

148 tumor microenvironment and activates innate immunity to orchestrate adaptive immunity when synergize

149 r the RLR family has broader effects on host immunity against other pathogen families remains to be f

150 djacent genes or the propagation of acquired immunity to other bacteria in the population, respective

151 eae, and cause infections that suppress host immunity to other pathogens.

152 ding SARS-CoV-2, and well as the duration of immunity to other viruses and virus vaccines.

153 of these functional antibodies in protective immunity against P. vivax malaria.

154 uine/chloroquine is safe and induces sterile immunity to P. falciparum in some recipients, but a sing

155 This indicates that the absence of immunity to P. kandelakii saliva in humans and dogs from

156 literature support a working model of innate immunity to papillomaviruses involving the activation of

157 ur studies support a working model of innate immunity to papillomaviruses, and the model provides a f

158 between exogenous and endogenous sources of immunity to parasite attack may represent an underapprec

159 otes hydrolytic elicitor release and acts in immunity against pathogenic Pseudomonas syringae strains

160 Long-term studies of immunity to pathogenic amyloid-beta (Abeta) in LOAD are

161 nity for therapy without compromising innate immunity against pathogens.

162 Humoral immunity to pathogens and other environmental challenges

163 C1s and cDC2s, which maintain the balance of immunity to pathogens and tolerance to self and microbio

164 are tissue-resident lymphocytes that promote immunity to pathogens at mucosal barriers, but the mecha

165 for dissecting protective versus detrimental immunity to pathogens that cause chronic infections such

166 mmunotherapy by capitalizing on pre-acquired immunity to pathogens to convert a weak antitumor immune

167 verse antibody repertoire, providing humoral immunity to pathogens, requires the participation of all

168 er (NK) cells are critical mediators of host immunity to pathogens.

169 tion even in mice with pre-existing adaptive immunity against PEG.

170 Many pathogens subvert intestinal immunity to persist within the gastrointestinal tract (G

171 CRISPR-Cas systems provide sequence-specific immunity against phages and mobile genetic elements usin

172 Type II CRISPR-Cas systems provide immunity against phages and plasmids that infect bacteri

173 Eliciting reliable and effective immunity against Plasmodium falciparum parasites remains

174 as valuable tools to interrogate protective immunity against Plasmodium infection.

175 elopment of long-lived and effective humoral immunity against Plasmodium takes many years and multipl

176 , children born after this date have limited immunity to prevent transmission.

177 OPV2 are the only available method to induce immunity to prevent transmission.

178 Aging impairs immunity to promote diseases, especially respiratory vir

179 sh local conditions that suppress antitumour immunity to promote tumorigenesis.

180 splant recipients can no longer rely on herd immunity to protect them from vaccine-preventable infect

181 4(pos)CD8(pos) thymocytes modulates cellular immunity against PRRSV and other pathogens.

182 tor of flg22 signaling and pattern-triggered immunity against Pseudomonas syringae pv tomato DC3000.

183 In line with the compromised immunity to Pst DC3000, ccc1 mutants show reduced expres

184 We found declining immunity to PV2, suggesting Vietnam is at risk for an ou

185 kettsial LPS, contributes to host protective immunity against R. australis These findings provide key

186 abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, which sugg

187 that SARS-CoV-2 infection induced protective immunity against reexposure in nonhuman primates.

188 ection with SARS-CoV-2 results in protective immunity against reexposure.

189 s a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a f

190 UF1, regulates the intestinal immunity to resist pathogen infection, which may be attr

191 ells (T(RM) cells) are critical for cellular immunity to respiratory pathogens and reside in both the

192 icle, we review findings of how aging alters immunity to respiratory viral infections to identify age

193 that BRM cells are an important component of immunity to respiratory viruses such as influenza virus

194 Moreover, cellular immunity to saliva or distinct salivary proteins protect

195 e loss of CD4 T cells, which are crucial for immunity to Salmonella infection.

196 e pathogen are shedding light on how humoral immunity to Salmonella operates.

197 ost Covid-19 patients, long-lived protective immunity against SARS-CoV-2 after primary infection migh

198 al immunoassays that can identify protective immunity against SARS-CoV-2 are needed to adapt quaranti

199 odies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity

200 on for understanding pathogenesis and innate immunity against SARS-CoV-2.

201 verifying diagnostic accuracy and protective immunity against SARS-CoV-2.

202 a serological study to define correlates of immunity against SARS-CoV-2.

203 didate vectored vaccine to elicit protective immunity against SARS-CoV-2.

204 tancing interventions in the absence of herd immunity against SARS-CoV-2.

205 to define clinical correlates of protective immunity against SARS-CoV-2.

206 Understanding adaptive immunity to SARS-CoV-2 is important for vaccine developm

207 Immunity to SARS-CoV-2 is likely to follow the same patt

208 ta provide fundamental insight into adaptive immunity to SARS-CoV-2 with the actively updated reposit

209 h understanding of the mechanisms of humoral immunity to SARS-CoV-2(4).

210 field studies to advance an understanding of immunity to SARS-CoV-2, leading to protection and durati

211 As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to devel

212 essing need for an in-depth understanding of immunity to SARS-CoV-2.

213 at better recapitulate natural CD8(+) T cell immunity to SARS-CoV-2.

214 ogenic inborn errors that disrupt protective immunity to SARS-CoV-2.

215 eded to determine the extent and duration of immunity to SARS-CoV-2.

216 and their potential relevance for effective immunity to SARS-CoV-2.

217 antibodies may be important for sterilizing immunity against secondary infection.

218 cted animals, immunizations enhanced humoral immunity to sequences located in the putative Tp0126 sur

219 pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coron

220 of infected patients, and the assessment of immunity against severe acute respiratory syndrome coron

221 Preexisting T cell immunity to severe acute respiratory syndrome coronaviru

222 yet major knowledge gaps remain about human immunity to severe acute respiratory syndrome coronaviru

223 An understanding of protective immunity to severe acute respiratory syndrome coronaviru

224 KRAS(G12D) tumours, which suggests adaptive immunity against shared antigens.

225 th vaccinia virus (VACV) elicits heterotypic immunity to smallpox, monkeypox, and mousepox, the mecha

226 hod licenses Th17 cells to confer long-lived immunity against solid malignancies via induction of sys

227 malaria transmission, and (iii) predict that immunity against some of the virulent effects of P. viva

228 lthough NK cells have been shown to regulate immunity to some infectious diseases, their role in immu

229 potential for gammadelta T cells to mediate immunity to Staphylococcus aureus in multiple tissue set

230 mming at this time point is not required for immunity to stem rust.

231 ne candidates that elicit broadly protective immunity against Strep A.

232 e previous exposure to one microbe can alter immunity to subsequent, non-related pathogens has been m

233 le approach to significantly improve humoral immunity to subunit vaccines using a clinical adjuvant.

234 mechanism that harnesses cellular antiviral immunity to suppress viral replication.

235 short-term strategy for conferring immediate immunity to susceptible individuals.

236 evelopment, the mechanisms of cell-intrinsic immunity to T. gondii in the brain and muscle, and the l

237 PR-associated) systems as a type of adaptive immunity to target and degrade foreign nucleic acids.

238 a central role in development of protective immunity against TB, in which they participate in the ac

239 ycan epitopes within AM in antibody-mediated immunity against TB.

240 e genes contribute to miR398b-regulated rice immunity against the blast fungus Magnaporthe oryzae.

241 The authors improve our understanding of immunity against the coronavirus spike glycoprotein and

242 he first vaccine capable of inducing sterile immunity against the current ASFV strain responsible for

243 ection but did not generate cross-protective immunity against the H3N2 influenza strain.

244 malaria which demonstrates that if adaptive immunity against the most virulent effects of malaria is

245 expression in tumour cells to enhance T-cell immunity against the tumours.

246 on patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.

247 V) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus

248 vated by HetR, suggesting that HetL provides immunity to the heterocyst.

249 a single infection often results in lifelong immunity to the infecting pathogen.

250 turn inhibits the development of protective immunity to the infection.

251 itres against autologous clade C Env at peak immunity to the longer, 12-month regimen: geometric mean

252 nstrained by ecological niches or population immunity to the M protein, or they may require several i

253 rmal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (

254 d increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated

255 While no preexisting immunity to the vector was observed, more than one-third

256 to detect antibodies to SARS-CoV-2 to assess immunity to the virus in the general population.

257 come pandemic and the duration of protective immunity to the virus is unknown.

258 ly focusing on pathogenetic aspects and host immunity to the virus.

259 ss II molecules are essential for protective immunity against them.

260 However, the high prevalence of preexisting immunity against these viruses in general populations wo

261 ilization of this pool by oxysterols confers immunity to these pathogens.

262 unappreciated layer of hepatocyte-intrinsic immunity to these positive-strand RNA viruses and identi

263 about how human antibodies confer functional immunity against this antigen.

264 on establishing natural and vaccine-induced immunity against this coronavirus and the disease, COVID

265 responses specific for RV-A, suggesting poor immunity to this species.Objectives: To ascertain and co

266 Eosinophils are effectors of immunity to tissue helminths.

267 isms of immunotherapy that activate the host immunity to treat cancers, unconventional immune-related

268 ines of T-helper 17 and T-helper 1 cells, in immunity to Trichophyton benhamiae (Heinen et al., 2018)

269 y to some infectious diseases, their role in immunity to Trypanosoma congolense has not been investig

270 e vaccine candidate and marker of protective immunity against tuberculosis, although the mechanisms u

271 These APECs redirect pre-existing CMV immunity against tumor cells in vitro and in mouse cance

272 are a promising approach for inducing T cell immunity to tumor neoantigens.

273 colorectal tumorigenesis, linking intrinsic immunity to tumor pathogenetics.

274 Immune checkpoint inhibition reactivates immunity against tumors that escaped immune surveillance

275 mice exhibited protective T cell-based host immunity to tumors in association with a decline in GrB-

276 ates effector function, as well as enhancing immunity against tumour and chronic virus.

277 ped, as were inoculations designed to confer immunity against typhoid and paratyphoid fevers.

278 ne substrate is bound, the catalyst has high immunity to typical sigma-base poisons due to the antibo

279 We aimed to estimate population immunity to vaccine-preventable diseases (VPDs) after va

280 wever, our knowledge of pre-existing humoral immunity against various AAV serotypes in cats is still

281 ry components in plant defense signaling and immunity against various microbial pathogens.

282 ses (Waks) are important components of plant immunity against various pathogens, including the bacter

283 This absence of immunity to vector saliva will influence the dynamics of

284 T cells (T(RM)s) confer rapid protection and immunity against viral infections.

285 nic ENDS vapor exposure downregulated innate immunity against viral pathogens in resident macrophages

286 cells are essential mediators of protective immunity to viral infection and malignant tumours and ar

287 IgG antibodies to induce protective adaptive immunity to viral infection when they selectively activa

288 (ssDNA) cytosine deaminases provides innate immunity against virus and transposon replication(1-4).

289 in prokaryotes, where they provide adaptive immunity against virus infection and plasmid transformat

290 nd mitochondrial activity, thereby promoting immunity against viruses and tumors.

291 CRISPR-Cas systems provide heritable immunity against viruses by capturing short invader DNA

292 CRISPR-Cas mechanism, that confers adaptive immunity against viruses.

293 R-Cas systems provide bacteria with adaptive immunity against viruses.

294 Immunity to viruses requires an array of critical cellul

295 the production of antibodies and protective immunity to viruses.

296 fascicularis), and-concomitantly-protective immunity against yellow fever virus.

297 Preexisting immunity to Zika virus (ZIKV) or dengue virus (DENV) may

298 Limited knowledge is available on intrinsic immunity against ZIKV in brains.

299 ntly do not know the longevity of protective immunity to ZIKV after a person becomes infected.

300 lasting immunity; however, the durability of immunity to ZIKV is unknown.